Cigarette sales and lung cancer deaths are the same curve, shifted 25 years.

For 18 years, we’ve been your trusted partner in the fight against cancer. Our steadfast mission is to provide accessible, expert-mediated information on current and emerging cancer management options to empower patients, caregivers, and health professionals to become direct

Progression-free survival and overall survival benefits of adding chemotherapy to gefitinib were sustained at 5 years, confirming earlier results reported at median follow-up of 17 months. ja.ma/3xOx344

We’re thrilled to share the Top 20 Voices in Lung Cancer on X, as chosen by their peers. 💫 These dedicated individuals are making a real impact in raising awareness, supporting patients, and driving research forward. Thank you for your tireless efforts and commitment. A

Benefit of WFH: At risk of being judged for frugality (or being cheap), I'll confess I now have several shirts w/a hole, permanent stain, fraying around collar, missing buttons, etc that are still suitable for zoom/Teams calls because offending problem isn't visible on camera.🤩

Riddle me this, Batman: why was contribution of phase not a prohibitive issue w/approval of pembro based on the KEYNOTE-671 trial but is now a critical factor for other trials with same design for same setting? 🤯

Honored to be in such an incredible ASCO FASCO Class! Congrats to all & thank you for working to make oncology better for patients, providers, & researchers! 🥰🙌👏💪🧬🩺💊🥼⚕️ Julia Close, MD, MBA Prof Michael Jefford Gretchen Kimmick Mark Lewis, MD, FASCO Ana Maria Lopez, MD, MPH, MACP Maryam Lustberg MD, MPH, FASCO DrKatyMoore

So, people with more aggressive cancer have worse outcomes... Perhaps it has less to do with the treatment pursued than the underlying biology of the cancer.

Appreciate need for clarity, but problematic when decision occurs after approval < 1 yr ago of pembro based on KN-671, w/same problematic design. Can U.S. FDA define which phase was critical in KN-671? Why didn't this issue come up before that decision?

H. Jack West, MD, FASCO U.S. FDA Yes absolutely, that’s the obvious question. I heard a comment saying “We did something before, doesn’t mean we need to do the same mistake again” Regardless, this will come up again with 77T and still may end up with the same fate- then I 🤔what was the point of the ODAC?

Esp when FDA says they will stop other trials from proceeding, optics look bad when they approve some agents in same setting based on trials they will now prohibit, & when these issues were clear before any of these approvals. Suggests different rules exist for diff companies.

BIG ANNOUNCEMENT! Skills Lab: Interpreting Clinical Research with Bishal Gyawali is now live Medscape Medscape Oncology ! Join me for a Series of Videos (with Transcripts) on how to interpret clinical research. I am super excited about this series where I can share with the audience

Medicine is the profession where when the canary in the coal mine dies, administrators just exclaim-- "Why can't we find more resilient canaries?"

#WCLC24 abstract titles released! Don't miss the plenary Sunday September 8th at 8:30am PDT - I am particularly eager to see the ivonescimab vs pembro HARMONi-2 data from Dr. Caicun Zhou, Neocoast-2 from Dr. Tina Cascone, and the 77T vs CM816 analysis from Dr. Patrick Forde!

She’s really talented! 🎻🥰

Our video of the GRACE Spanish Targeted Therapy forum is available online youtube.com/watch?v=M5vqx9… with Ivy Riano, M.D. Dr. Estela Rodriguez Ana I. Velázquez Mañana, MD, MSc, FASCO Claudio Martin Andres F. Cardona #lungcancer #lungcancerawareness #lcsm H. Jack West, MD, FASCO

Will this actually change practice for anyone? If people are already doing neoadjuvant chemo/nivo or peri-operative chemo/pembro f/b pembro post-op, is anyone switching to AEGEAN regimen? If so, what is driving that?

Oncology Brothers FDA Oncology Bijoy Telivala Santhosh Ambika gilberto lopes H. Jack West, MD, FASCO Narjust Florez, MD, FASCO Charu Aggarwal, MD, MPH, FASCO LUNGevity Foundation Dr. Amy C. Moore part of the toxicity table from the NEJM paper below much higher rate of grade 3 or greater events much higher rate of dose interruption much higher rate of drug discontinuation

Our GRACE Spanish Therapy forum dont miss the presentations cancergrace.org/post/vod-foro-… Ivy Riano, M.D. Dr. Estela Rodriguez Andres F. Cardona Claudio Martin #lungcancer #lcsm

Lung pathology imaging signs